Andy Cohen TRT: The Private-Clinic Pathway They Likely Used

Why Andy Cohen's Openness About TRT Matters Clinically

Cohen is unusual among public figures because he has not treated hormone therapy as a secret. In interviews and on his own SiriusXM radio show, he has referenced HRT as part of his personal health routine. That candor removes the need for speculation about whether he uses testosterone and lets the clinical conversation focus on the more useful question: what does that treatment actually look like inside a private clinic?

The Broader Context of Male HRT Disclosure

Public disclosure by recognizable figures tends to drive search volume and, more usefully, drives men who have been quietly experiencing symptoms to finally book a lab appointment. A 2020 analysis published in JAMA Internal Medicine estimated that 2.9 million U.S. Men filled at least one testosterone prescription in 2013, a figure that had grown roughly 3-fold in the preceding decade [1]. That growth was partly cultural. When someone with Cohen's platform describes fatigue, lower libido, or mood changes as treatable medical conditions rather than inevitable aging, men pay attention.

What "Private Clinic" Actually Means

A private or concierge men's health clinic operates outside the standard insurance-network model. The physician or PA sees fewer patients per day, orders a comprehensive hormone panel rather than a single testosterone value, and schedules follow-up calls between office visits. Telehealth platforms such as Defy Medical, Evolve Telemed, and similar services replicate this model digitally. The clinical standards, however, should mirror those published by the Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy in men [2].

The Diagnostic Pathway: How Clinicians Confirm Low Testosterone

Before any prescription is written, a legitimate clinic completes a structured diagnostic process. Skipping this step is a red flag that separates evidence-based practices from "script mills."

Step 1: Symptom Inventory

Clinicians typically use a validated questionnaire. The Aging Males' Symptoms (AMS) scale and the ADAM (Androgen Deficiency in Aging Males) questionnaire are both in common use. A score suggesting androgen deficiency moves the patient to lab confirmation [3]. Symptoms that commonly bring men in include reduced libido, fatigue, difficulty maintaining muscle despite consistent training, mood changes, and poor sleep quality, all of which Cohen has referenced in the context of his own health in public interviews.

Step 2: Morning Blood Draw, Twice

The Endocrine Society guideline is specific: total testosterone must be measured in the morning (between 7 a.m. And 10 a.m., when levels peak) on at least two separate occasions before a diagnosis of hypogonadism is confirmed [2]. A single low value is not sufficient. The diagnostic threshold is a total testosterone below 300 ng/dL, though many experienced clinicians also assess free testosterone, which may be low even when total testosterone sits in the low-normal range.

Step 3: Differential Workup

Low testosterone is a symptom, not always a primary diagnosis. A thorough clinic orders LH and FSH to distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic origin). A prolactin value rules out pituitary adenoma. Thyroid function (TSH, free T4) and a complete metabolic panel round out the picture. The FDA label for testosterone cypionate specifies that hypogonadism must be confirmed by clinical features and lab results before initiating therapy [4].

The Protocol: What a Private Clinic Would Most Likely Prescribe

Given Cohen's age bracket (mid-50s), general fitness, and absence of any disclosed fertility goals for future biological children, a private clinic would almost certainly reach for one of two standard formulations.

Testosterone Cypionate: The Most Common Starting Point

Testosterone cypionate (brand name Depo-Testosterone) is an FDA-approved injectable esterified testosterone with a half-life of approximately 8 days. The standard private-clinic starting dose for a man with confirmed hypogonadism is 100 mg injected subcutaneously (SubQ) or intramuscularly (IM) once weekly [4]. Some clinicians use 50 mg twice weekly to reduce peak-to-trough fluctuation and minimize estradiol conversion.

Weekly SubQ injections into the abdomen or thigh have become the preferred method at many concierge practices because absorption is reliable, patients self-administer easily, and the smaller needle (typically 27 to 29 gauge, 5/8 inch) reduces injection-site discomfort compared with traditional IM dosing.

Target serum total testosterone on a weekly cypionate protocol is generally 600 to 900 ng/dL at mid-cycle (3 to 4 days post-injection), though some physicians and their patients accept the high-normal range of 900 to 1,100 ng/dL if the patient tolerates it well without hematocrit elevation.

Testosterone Enanthate: A Close Second

Testosterone enanthate has a nearly identical pharmacokinetic profile (half-life approximately 7 to 10 days) and is used interchangeably with cypionate in most protocols. It is available as a compounded formulation in many private clinics that operate their own pharmacy relationships.

Topical Options and Why They Are Less Common at Private Clinics

Transdermal gels (AndroGel, Testim, Fortesta) and creams are FDA-approved and avoid the needle entirely. Their main limitation in private-clinic settings is variable absorption, which makes achieving a predictable steady-state harder. Scrotal testosterone cream has gained traction in some concierge practices because the scrotal skin absorbs testosterone more efficiently than arm or shoulder skin and also produces some natural conversion to DHT, which some physicians believe contributes to libido response. For a high-profile patient whose schedule demands predictability, injectables remain the dominant choice.

Estradiol Management: The Step Most Clinics Get Wrong

Testosterone aromatizes to estradiol (E2) in adipose tissue. For men who carry moderate body fat or who are on higher doses, estradiol can rise enough to cause symptoms: nipple sensitivity, water retention, mood instability, and reduced libido. Managing this without over-suppressing estradiol is one of the more technically demanding parts of male TRT.

Aromatase Inhibitors: Anastrozole

Anastrozole 0.25 to 0.5 mg taken orally one to three times per week is the standard tool. The goal is to keep estradiol in the 20 to 30 pg/mL range on sensitive (LC/MS-MS) assay. Crashing estradiol below 15 pg/mL causes joint pain, low libido, and mood disorders that often feel worse than the original hypogonadism [5]. A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that men require a physiologic level of estradiol for bone density, cardiovascular health, and sexual function [5].

When Clinicians Skip the AI

Many experienced TRT physicians now advocate a "start low, skip the AI" approach: begin at 100 mg cypionate weekly, check estradiol at 6 weeks, and add anastrozole only if the patient reports symptoms AND the sensitive estradiol value exceeds 40 to 50 pg/mL. This prevents the over-prescription of anastrozole that was common in early concierge TRT practices throughout the 2010s.

Monitoring Schedule at a Private Clinic

Cohen's demanding production schedule at Bravo would make quarterly blood draws inconvenient. Private clinics accommodate this reality with at-home lab orders through services like LabCorp At Home or Quest Diagnostics Mobile.

The 6-Week Check

Six weeks after initiation, the standard panel includes: total testosterone (morning draw), free testosterone, sensitive estradiol, hematocrit, and a lipid panel. This early check catches two common problems: testosterone sitting outside the target range (requiring dose adjustment) and hematocrit rising above 54%, which is the threshold at which most guidelines recommend dose reduction or therapeutic phlebotomy [2].

Ongoing Quarterly and Biannual Monitoring

After the 6-week adjustment, most private clinics move to quarterly labs for the first year, then shift to biannual monitoring once the patient is stable. PSA is checked at baseline and at 3 to 6 months in men over 40. The Endocrine Society guideline states: "We recommend evaluating prostate safety by measuring PSA levels before initiating testosterone therapy in men at increased risk for prostate carcinoma" [2]. That recommendation applies to nearly every man over 50.

A hematocrit above 54% on two consecutive draws is considered grounds for dose reduction, therapeutic phlebotomy (donating blood), or temporary cessation. Polycythemia is the most common clinically significant adverse effect of TRT in otherwise healthy men [6].

Fertility Preservation: The Question Private Clinics Must Ask

Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. This suppresses endogenous testosterone production and, more clinically relevant for many patients, shuts down spermatogenesis. For Cohen, who has children via surrogacy and may not have active fertility goals, this consideration may be less pressing. The clinic still must document the discussion.

hCG Co-Administration

Human chorionic gonadotropin (hCG) is an LH analog. At doses of 500 to 1,500 IU subcutaneously two to three times weekly, it maintains intratesticular testosterone production, prevents testicular atrophy, and preserves some degree of spermatogenesis during TRT [7]. Many private clinics co-prescribe hCG from the outset; others add it only at patient request.

Clomiphene as a Monotherapy Alternative

Clomiphene citrate (Clomid), used off-label in men, stimulates LH and FSH release by blocking hypothalamic estrogen receptors. It raises endogenous testosterone without suppressing the HPG axis, making it an option for men who want higher testosterone and preserved fertility. A 2019 study in Andrology (N=92) found that clomiphene raised total testosterone from a mean of 209 ng/dL to 512 ng/dL over 3 months without significantly affecting sperm concentration [8].

The Financial Reality of the Private-Clinic Model

Private men's health clinics typically operate on a cash-pay model. Insurance coverage for TRT is inconsistent and often requires extensive prior-authorization documentation even when hypogonadism is clearly confirmed. A realistic cost breakdown for the first year of a private-clinic TRT protocol looks roughly like this:

• Initial consultation and hormone panel: $200, $500
• Monthly testosterone cypionate (10 mL vial at 200 mg/mL): $30, $80 through a compounding pharmacy or $120, $180 for brand-name Depo-Testosterone
• Anastrozole (if indicated): $15, $40/month compounded
• hCG (if indicated): $80, $150/month compounded
• Quarterly labs: $150, $400 per draw without insurance

For someone at Cohen's income level, the cost is trivial. For the average American man, the all-in annual cost of $2,000, $5,000 is a significant barrier, which is one reason telehealth TRT platforms have competed hard on price, some offering cypionate protocols starting at $99/month with labs included.

The Testosterone Trials: The Best Evidence for What Cohen's Protocol Would Achieve

The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled trials conducted at 12 U.S. Sites in men 65 and older with total testosterone below 275 ng/dL (N=790). Published in the New England Journal of Medicine in 2016, they remain the most rigorous evidence base for TRT outcomes in older men [9].

Key findings at 12 months:

• Sexual Activity Trial: testosterone gel (target level 500 to 1,000 ng/dL) produced significantly greater improvements in sexual desire, erectile function, and sexual activity versus placebo (P<0.001) [9].
• Physical Function Trial: improvement in walking distance was greater in the testosterone group but did not reach the pre-specified threshold for clinical significance.
• Vitality Trial: testosterone produced a statistically significant improvement in mood and depressive symptoms on the Patient Health Questionnaire-9 (PHQ-9) at 12 months.

The TTrials used a transdermal gel. Private clinics argue that injectable cypionate produces more predictable and often higher mid-cycle testosterone levels than gel, though no head-to-head trial of comparable size has tested that assumption directly.

The table below outlines the private-clinic decision framework a physician would apply to a patient matching Cohen's profile:

| Clinical Variable | Threshold or Target | Action if Outside Range | |---|---|---| | Total testosterone (morning) | <300 ng/dL on 2 draws | Confirm diagnosis, initiate therapy | | Free testosterone | <65 pg/mL (calculated) | Consider treatment even if total is borderline | | Estradiol (sensitive LC/MS) | 20 to 30 pg/mL on therapy | Add anastrozole if symptomatic and >40 pg/mL | | Hematocrit | <54% | Dose-reduce or phlebotomize if exceeded | | PSA | Baseline + 3 to 6 month recheck | Urology referral if rise >1.4 ng/mL in 12 months | | LH/FSH at baseline | Low or inappropriately normal | Secondary hypogonadism workup; consider hCG |

What the Evidence Says About Long-Term Safety

The cardiovascular safety of TRT generated significant controversy after a 2010 trial in older men with mobility limitations was stopped early due to cardiovascular events [10]. Subsequent analysis showed that trial enrolled men with unusually high baseline cardiovascular risk.

Larger and better-controlled studies have been more reassuring. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, was specifically designed to evaluate cardiovascular safety of testosterone replacement in men with hypogonadism and high cardiovascular risk. It found that testosterone was non-inferior to placebo for the primary composite of major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [11]. The Endocrine Society's 2018 guideline does not list stable cardiovascular disease as an absolute contraindication to TRT, though it recommends physician judgment and monitoring [2].

Polycythemia, as noted, is the most consistent safety concern. Venous thromboembolism (VTE) risk appears modestly elevated in the first 6 months of therapy, according to a 2019 meta-analysis in BMJ Open (RR 1.34, 95% CI 1.03 to 1.75) [6].